Remove 2024 Remove Compounding Remove Method Validation
article thumbnail

FDA guidance highlights E&L considerations for ophthalmic drug products

European Pharmaceutical Review

Over time, these can leach “low molecular weight compounds” such as plasticisers, stabilisers and binding agents from CCS components or from labelling components, like inks or adhesives into the drug product. The guidance document also emphasised semipermeable CCSs as another factor to consider in relation to E&Ls.